{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:23:53Z","timestamp":1787009033655,"version":"build-2736575974"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Paratek Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The current antibiotic arsenal for the treatment of Mycobacterium avium infections is limited and new treatment options are needed. This exploratory study assessed the in vitro activity of omadacycline against M. avium alone and combined with current guideline-recommended antibiotics and the ability of omadacycline to prevent the emergence of antibiotic resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The activity of omadacycline and comparator antibiotics against M. avium was studied by minimum inhibitory concentration (MIC) assays and time-kill kinetics assays to investigate time- and concentration-dependent activity patterns. Omadacycline\u2019s ability to prevent clarithromycin and amikacin resistance was investigated by phenotypic and molecular assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The MIC of omadacycline was impacted by medium composition: a higher MIC was found in CAMHB (128\u2005mg\/L) versus Middlebrook broth (8\u2005mg\/L). MIC values were also impacted by omadacycline instability in solution over time and daily drug supplementation reduced the MIC to 1\u2005mg\/L. In time-kill assays, omadacycline demonstrated time- and concentration-dependent activity. Omadacycline-containing drug combinations resulted in varying degrees of enhanced activity, which was most apparent for omadacycline plus amikacin. Omadacycline prevented amikacin MICs from increasing and impeded the emergence of rrs mutations observed with amikacin alone. While enhanced activity of omadacycline plus clarithromycin was less pronounced, rrl mutations were not detected in the presence of omadacycline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Omadacycline demonstrated in vitro activity against M. avium, particularly in combination with amikacin. Emergence of clarithromycin and amikacin resistance seemed to be prevented by co-exposure to omadacycline. Further research is warranted to assess omadacycline\u2019s role in treating M. avium disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf413","type":"journal-article","created":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:57:10Z","timestamp":1762649830000},"source":"Crossref","is-referenced-by-count":3,"title":["Omadacycline as a drug candidate for\n                    <i>Mycobacterium avium<\/i>\n                    infections:\n                    <i>in vitro<\/i>\n                    insights on single and combination therapies"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9910-156X","authenticated-orcid":false,"given":"Saskia E","family":"Mudde","sequence":"first","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Centre , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri\u00ebtte M","family":"Meliefste","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Centre , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3439-0903","authenticated-orcid":false,"given":"Corn\u00e9 H W","family":"Klaassen","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Centre , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole C","family":"Ammerman","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Centre , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica V","family":"Pierce","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc. , King of Prussia, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5625-0792","authenticated-orcid":false,"given":"Alisa W","family":"Serio","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc. , King of Prussia, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurriaan E M","family":"De Steenwinkel","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Centre , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannelore I","family":"Bax","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Centre , Rotterdam ,","place":["The Netherlands"]},{"name":"Department of Internal Medicine, Section of Infectious Diseases, Erasmus University Medical Centre , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"2026011413274929000_dkaf413-B1","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciaa241","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"71","author":"Daley","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026011413274929000_dkaf413-B2","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1378\/chest.15-0543","article-title":"Long-term follow-up of Mycobacterium avium Complex lung disease in patients treated with regimens including clofazimine and\/or rifampin","volume":"149","author":"Jarand","year":"2016","journal-title":"Chest"},{"key":"2026011413274929000_dkaf413-B3","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1378\/chest.124.4.1482","article-title":"Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine","volume":"124","author":"Field","year":"2003","journal-title":"Chest"},{"key":"2026011413274929000_dkaf413-B4","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.chest.2023.11.038","article-title":"Safety and efficacy of clofazimine as an alternative for rifampicin in Mycobacterium avium Complex pulmonary disease treatment: outcomes of a randomized trial","volume":"165","author":"Zweijpfenning","year":"2024","journal-title":"Chest"},{"key":"2026011413274929000_dkaf413-B5","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1093\/cid\/cix517","article-title":"Treatment outcomes of Mycobacterium avium Complex lung disease: a systematic review and meta-analysis","volume":"65","author":"Kwak","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2026011413274929000_dkaf413-B6","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.chest.2018.01.024","article-title":"Microbiologic outcome of interventions against Mycobacterium avium Complex pulmonary disease: a systematic review","volume":"153","author":"Diel","year":"2018","journal-title":"Chest"},{"key":"2026011413274929000_dkaf413-B7","doi-asserted-by":"publisher","first-page":"e256","DOI":"10.1093\/cid\/ciaa1361","article-title":"Management of drug toxicity in Mycobacterium avium Complex pulmonary disease: an expert panel survey","volume":"73","author":"van Ingen","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026011413274929000_dkaf413-B8","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1093\/jac\/dkz267","article-title":"Omadacycline as a promising new agent for the treatment of infections with Mycobacterium abscessus","volume":"74","author":"Bax","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026011413274929000_dkaf413-B9","doi-asserted-by":"publisher","first-page":"e0170421","DOI":"10.1128\/AAC.01704-21","article-title":"Potency of omadacycline against Mycobacteroides abscessus clinical isolates in vitro and in a mouse model of pulmonary infection","volume":"66","author":"Nicklas","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413274929000_dkaf413-B10","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.ijid.2022.06.061","article-title":"Omadacycline in first-line combination therapy for pulmonary Mycobacterium abscessus infection: a case series","volume":"122","author":"Duah","year":"2022","journal-title":"Int J Infect Dis"},{"key":"2026011413274929000_dkaf413-B11","doi-asserted-by":"publisher","first-page":"102269","DOI":"10.1016\/j.tube.2022.102269","article-title":"Challenges and a potential solution to perform drug susceptibility testing of omadacycline against nontuberculous mycobacteria","volume":"137","author":"Shankar","year":"2022","journal-title":"Tuberculosis (Edinb)"},{"key":"2026011413274929000_dkaf413-B12","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/1440-1681.13777","article-title":"In vitro susceptibility testing of tetracycline-class antibiotics against slowly growing non-tuberculous mycobacteria","volume":"50","author":"Li","year":"2023","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2026011413274929000_dkaf413-B13","doi-asserted-by":"publisher","first-page":"e01947-20","DOI":"10.1128\/AAC.01947-20","article-title":"In Vitro susceptibility testing of omadacycline against nontuberculous mycobacteria","volume":"65","author":"Brown-Elliott","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413274929000_dkaf413-B14","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1093\/jac\/dkac068","article-title":"Omadacycline efficacy in the hollow fibre system model of pulmonary Mycobacterium avium complex and potency at clinically attainable doses","volume":"77","author":"Chapagain","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2026011413274929000_dkaf413-B15","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1128\/AAC.39.12.2625","article-title":"Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease","volume":"39","author":"Nash","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413274929000_dkaf413-B16","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/infdis\/174.2.354","article-title":"Molecular mechanisms of clarithromycin resistance in Mycobacterium avium: observation of multiple 23S rDNA mutations in a clonal population","volume":"174","author":"Meier","year":"1996","journal-title":"J Infect Dis"},{"key":"2026011413274929000_dkaf413-B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1054\/tuld.1999.0227","article-title":"Molecular basis of clarithromycin-resistance in Mycobacterium avium intracellulare complex","volume":"80","author":"Jamal","year":"2000","journal-title":"Tuber Lung Dis"},{"key":"2026011413274929000_dkaf413-B18","doi-asserted-by":"publisher","first-page":"7153","DOI":"10.1128\/AAC.01027-15","article-title":"Assessing primary and secondary resistance to clarithromycin and amikacin in infections due to Mycobacterium avium complex","volume":"59","author":"Renvois\u00e9","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413274929000_dkaf413-B19","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1128\/JCM.01612-13","article-title":"In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates","volume":"51","author":"Brown-Elliott","year":"2013","journal-title":"J Clin Microbiol"},{"key":"2026011413274929000_dkaf413-B20","doi-asserted-by":"publisher","first-page":"6108","DOI":"10.1038\/s41598-021-85721-5","article-title":"Association between 16S rRNA gene mutations and susceptibility to amikacin in Mycobacterium avium Complex and Mycobacterium abscessus clinical isolates","volume":"11","author":"Kim","year":"2021","journal-title":"Sci Rep"},{"key":"2026011413274929000_dkaf413-B21","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jgar.2022.10.015","article-title":"Unraveling antibiotic resistance mechanisms in Mycobacterium abscessus: the potential role of efflux pumps","volume":"31","author":"Mudde","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"2026011413274929000_dkaf413-B22","volume-title":"Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes","author":"CLSI","year":"2018","edition":"3rd ed"},{"key":"2026011413274929000_dkaf413-B23","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1128\/AAC.02864-15","article-title":"Tigecycline potentiates clarithromycin activity against Mycobacterium avium In Vitro","volume":"60","author":"Bax","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413274929000_dkaf413-B24","doi-asserted-by":"publisher","first-page":"e0294677","DOI":"10.1371\/journal.pone.0294677","article-title":"Phenotypic drug-susceptibility profiles and genetic analysis based on whole-genome sequencing of Mycobacterium avium complex isolates in Thailand","volume":"18","author":"Sirichoat","year":"2023","journal-title":"PLoS One"},{"key":"2026011413274929000_dkaf413-B25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.tube.2017.04.010","article-title":"The role of the time-kill kinetics assay as part of a preclinical modeling framework for assessing the activity of anti-tuberculosis drugs","volume":"105","author":"Bax","year":"2017","journal-title":"Tuberculosis (Edinb)"},{"key":"2026011413274929000_dkaf413-B26","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jgar.2023.07.007","article-title":"The potential role of drug transporters and amikacin modifying enzymes in M. avium","volume":"34","author":"Schildkraut","year":"2023","journal-title":"J Glob Antimicrob Resist"},{"key":"2026011413274929000_dkaf413-B27","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1164\/rccm.201604-0700OC","article-title":"Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease","volume":"195","author":"Olivier","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026011413274929000_dkaf413-B28","doi-asserted-by":"publisher","first-page":"e0008424","DOI":"10.1128\/aac.00084-24","article-title":"Phenotypic amikacin resistance may not indicate poor response to amikacin in Mycobacterium avium complex pulmonary disease","volume":"68","author":"Minuk","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413274929000_dkaf413-B29","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1128\/AAC.02615-15","article-title":"Clofazimine prevents the regrowth of Mycobacterium abscessus and Mycobacterium avium type strains exposed to amikacin and clarithromycin","volume":"60","author":"Ferro","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413274929000_dkaf413-B30","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2026011413274929000_dkaf413-B31","doi-asserted-by":"publisher","first-page":"6758","DOI":"10.1128\/AAC.01240-16","article-title":"Clinical characteristics, treatment outcomes, and resistance mutations associated with macrolide-resistant Mycobacterium avium Complex lung disease","volume":"60","author":"Moon","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413274929000_dkaf413-B32","doi-asserted-by":"publisher","first-page":"107366","DOI":"10.1016\/j.rmed.2023.107366","article-title":"Monotherapy: key cause of macrolide-resistant Mycobacterium avium complex disease","volume":"217","author":"Loewenstein","year":"2023","journal-title":"Respir Med"},{"key":"2026011413274929000_dkaf413-B33","doi-asserted-by":"publisher","first-page":"e01487-17","DOI":"10.1128\/AAC.01487-17","article-title":"Safety and pharmacokinetics of the aminomethylcycline antibiotic omadacycline administered to healthy subjects in oral multiple-dose regimens","volume":"62","author":"Bundrant","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413274929000_dkaf413-B34","author":"Food and Drug Administration"},{"key":"2026011413274929000_dkaf413-B35","doi-asserted-by":"publisher","first-page":"e01135-17","DOI":"10.1128\/AAC.01135-17","article-title":"Comparison of omadacycline and tigecycline pharmacokinetics in the plasma, epithelial lining fluid, and alveolar cells of healthy adult subjects","volume":"61","author":"Gotfried","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413274929000_dkaf413-B36","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3138\/jammi.2019-0019","article-title":"Underutilization of nontuberculous mycobacterial drug susceptibility testing in Ontario, Canada, 2010\u20132015","volume":"5","author":"Andrews","year":"2020","journal-title":"J Assoc Med Microbiol Infect Dis Can"},{"key":"2026011413274929000_dkaf413-B37","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ijid.2016.12.027","article-title":"Minimum inhibitory concentration distirbutions for Mycobacterium avium complex-towards evidence-based susceptibility breakpoints","volume":"55","author":"Sch\u00f6n","year":"2017","journal-title":"Int J infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/1\/dkaf413\/65224130\/dkaf413.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/1\/dkaf413\/65224130\/dkaf413.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:27:55Z","timestamp":1768415275000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkaf413\/8314988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf413","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,11,5]]},"article-number":"dkaf413"}}